Trials / Active Not Recruiting
Active Not RecruitingNCT02414022
Economic Analysis of Alliance A041202 CLL Study
Prospective Economic Analysis: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib + Rituximab vs Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 55 (actual)
- Sponsor
- Canadian Cancer Trials Group · Network
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The prospective cost-effectiveness (cost-utility) analysis from the perspective of the Canadian public healthcare system was completed in 2021. Health state utilities were collected using the EuroQOL EQ-5D instrument with Canadian tarrifs applied to calculate quality-adjusted life-years (QALYs). Costs were applied to resource utilization data (expressed in 20196 US dollars). We examined costs and outcomes (QALYs) associated with ibrutinib with rituximab (IR) and BR therapy.
Conditions
Timeline
- Start date
- 2015-04-15
- Primary completion
- 2019-04-05
- Completion
- 2026-04-09
- First posted
- 2015-04-10
- Last updated
- 2025-06-11
Locations
15 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT02414022. Inclusion in this directory is not an endorsement.